Combination vaccine against PCV2 and PRRS virus infection comprising albumin
The present invention pertains to a vaccine for use in prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2) and an infection with PRRS virus, the vaccine comprising in combination non-replicating immunogen of porcine circovirus type 2 and live attenuated PRRS virus, wherein the vaccine additionally comprises albumin.
1. A vaccine comprising in combination a non-replicating immunogen of porcine circovirus type 2 (PCV2), a live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, and albumin.
2. A vaccine of claim 1 , wherein the vaccine comprises ovalbumin.
3. A vaccine of claim 1 , wherein the albumin concentration is between 0.1 and 10% (w/w).
4. A vaccine of claim 1 , wherein the non-replicating immunogen of PCV2 is recombinantly expressed ORF2 protein of PCV2.
5. A vaccine of claim 1 , wherein the non-replicating immunogen of PCV2 is baculovirus expressed ORF2 protein of PCV2.
6. A vaccine of claim 1 , wherein the vaccine comprises in addition non-replicating immunogen of Mycoplasma hyopneumoniae.
7. A vaccine for use in prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2), an infection with porcine reproductive and respiratory syndrome (PRRS) virus, or an infection of both PCV2 and PRRS virus, wherein the vaccine comprises in combination non-replicating immunogen of PCV2, live attenuated PRRS virus, and albumin.
8. A vaccine of claim 7 , wherein said vaccine is administered into the dermis of the animal.
9. A vaccine of claim 7 , wherein said vaccine is administered by a single dose.
10. A vaccine of claim 7 , wherein said vaccine is administered with a needle-less vaccination device.
11. A vaccine of claim 7 , wherein immunogen of PCV2 and the live attenuated PRRS virus are combined in the vaccine within 24 hours before administration.
12. A vaccine of claim 7 , wherein immunogen of PCV2 and the live attenuated PRRS virus are combined in the vaccine within 6 hours before administration.
13. A vaccine of claim 11 , wherein prior to combination of the immunogens, the albumin is present in combination with the immunogen of PRRS virus.
14. A method for prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2), an infection with porcine reproductive and respiratory syndrome (PRRS) virus, or an infection of both PCV2 and PRRS virus, by administrating to the animal a vaccine comprising in combination non-replicating immunogen of PCV2, live attenuated PRRS virus, and albumin.
15. A method of manufacturing a vaccine comprising the non-replicating immunogen of porcine circovirus type 2 (PCV2), the live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, and albumin, for administration to an animal to prophylactically treat the animal against an infection with PCV2, an infection with PRRS virus, or an infection of both PCV2 and PRRS virus.